Acute Myocardial Infarction Market: Expanding Therapeutic Innovation, Secondary Prevention Strategies, and Emerging Pipeline Therapies to Drive Growth Through 2036
New York, USA – September 29, 2026 – The Acute Myocardial Infarction (AMI) market is witnessing continued transformation, driven by the substantial global disease burden, advances in rapid diagnosis and reperfusion, increasing emphasis on secondary cardiovascular prevention, and the development of therapies targeting residual thrombotic, inflammatory, lipid-driven, and ischemia-reperfusion risks. The current treatment landscape is centered on antiplatelets, anticoagulants, beta-blockers, vasodilators, lipid-lowering therapies, ACE inhibitors, ARBs, and other cardioprotective agents, while emerging therapies such as selatogrel, dapagliflozin, FDY-5301, dutogliptin, and zalunfiban are being investigated to address additional treatment gaps.
According to DelveInsight, the Acute Myocardial Infarction market across the 7MM was valued at approximately USD 1.6 billion in 2025 and is projected to reach approximately USD 6.0 billion by 2036, growing at a CAGR of approximately 13% during 2026–2036. The seven major markets include the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
DelveInsight’s report, “Acute Myocardial Infarction Market Insights, Epidemiology and Market Forecast – 2036,” provides comprehensive insights into AMI epidemiology, patient burden, treatment practices, marketed and emerging therapies, competitive dynamics, market size, unmet needs, reimbursement, pricing, and future opportunities across the 7MM.
Key Takeaways
- The 7MM Acute Myocardial Infarction market size was approximately USD 1.6 billion in 2025.
- The AMI market is projected to reach approximately USD 6.0 billion by 2036.
- The market is expected to grow at approximately 13% CAGR during 2026–2036.
- Approximately 1.5 million AMI incident cases were estimated across the 7MM in 2025.
- The United States accounted for the largest share of the AMI market among the 7MM.
- Approximately 950,000 male and 550,000 female AMI incident cases were estimated across the 7MM in 2025.
- Approximately 510,000 STEMI and 990,000 NSTEMI cases were estimated across the 7MM in 2025.
- Current treatment is centered on rapid reperfusion, antithrombotic therapy, lipid lowering, and long-term cardiovascular risk reduction.
- LODOCO (colchicine), TNKase (tenecteplase), and REPATHA (evolocumab) are among the marketed therapies highlighted in the report.
- The emerging pipeline includes Selatogrel, FARXIGA/FORXIGA (dapagliflozin), FDY-5301, dutogliptin, zalunfiban, ziltivekimab, milvexian, and olpasiran.
Keen to know more about the Acute Myocardial Infarction market? Request our sample page at: https://www.delveinsight.com/sample-request/acute-myocardial-infarction-ami-market
Key Factors Driving the Acute Myocardial Infarction Market
Expanding Therapeutic Landscape and Innovation
The AMI treatment landscape is expanding beyond traditional reperfusion and antithrombotic approaches. Emerging therapies are targeting residual cardiovascular risk, inflammation, thrombosis, lipid-mediated risk, and ischemia-reperfusion injury. DelveInsight identifies pipeline assets from companies including Amgen, Novo Nordisk, Bristol Myers Squibb, Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, and Faraday Pharmaceuticals as important contributors to future therapeutic innovation.
Growing Focus on Preventive and Long-term Management
The treatment paradigm is increasingly extending beyond acute intervention toward long-term secondary prevention. Lipid-lowering therapies, antiplatelet agents, and anti-inflammatory treatments are being used to address residual cardiovascular risk and reduce the likelihood of recurrent events following myocardial infarction.
Rising Healthcare Expenditure and Disease Awareness
Increasing healthcare expenditure, improved access to cardiovascular interventions, and greater awareness of cardiovascular disease are supporting the AMI treatment market across developed markets. The United States remains the largest market because of its disease burden, healthcare infrastructure, access to PCI, and adoption of novel therapies.
Advancements in Diagnosis
The widespread adoption of cardiac biomarkers, particularly troponins, has improved the ability to identify myocardial injury. ECG remains essential for distinguishing STEMI from NSTEMI and determining appropriate urgent treatment, while echocardiography and coronary angiography provide additional diagnostic and interventional information.
Competitive Landscape
The Acute Myocardial Infarction competitive landscape includes established pharmaceutical companies and emerging biotechnology companies developing therapies across acute reperfusion, antithrombotic treatment, lipid lowering, inflammation control, cardioprotection, and ischemia-reperfusion injury.
Key companies highlighted by DelveInsight include:
- AGEPHA Pharma
- Genentech
- Amgen
- Merck
- Regeneron and Sanofi
- Idorsia Pharmaceuticals
- Viatris
- Recardio
- AstraZeneca
- Faraday Pharmaceuticals
- Novo Nordisk
- Bristol Myers Squibb
- Johnson & Johnson Innovative Medicine
- CellProthera
- BioCardia
- Kancera
- Arrowhead Pharmaceuticals
The competitive landscape includes marketed therapies such as LODOCO, TNKase, and REPATHA, together with a pipeline of mid- and late-stage candidates addressing different aspects of AMI management.
Discover more about therapies set to impact the Acute Myocardial Infarction market @ DelveInsight – Acute Myocardial Infarction Market Insights
Recent Developments in the Acute Myocardial Infarction Market
- June 2024: Faraday Pharmaceuticals announced completion of enrollment in its pivotal Phase III Iocyte AMI-3 trial evaluating FDY-5301 for ischemia-reperfusion injury following myocardial infarction.
- February 2024: Idorsia Pharmaceuticals entered into a global research and development collaboration with Viatris covering the development and commercialization of selatogrel and cenerimod, including an upfront payment of USD 350 million, along with potential development and regulatory milestone payments and sales-based payments.
- July 2020: AstraZeneca announced that FARXIGA (dapagliflozin) received US FDA Fast Track designation for heart failure following AMI, supporting its development in the Phase III DAPA-MI study.
What is Acute Myocardial Infarction?
Acute Myocardial Infarction (AMI) is characterized by ischemic necrosis of myocardial tissue and most commonly results from coronary artery disease, acute atherosclerotic plaque rupture, and subsequent thrombosis. AMI generally occurs within the spectrum of acute coronary syndrome (ACS) and can present with chest pain or pressure, dyspnea, nausea, diaphoresis, and other symptoms.
AMI is broadly classified into ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). It can also be categorized as Type 1 MI, generally associated with atherothrombotic events, and Type 2 MI, which is associated with an imbalance between myocardial oxygen supply and demand.
Major risk factors include hypertension, diabetes, smoking, and dyslipidemia. Early diagnosis and rapid restoration of myocardial blood flow are essential components of AMI management.
Acute Myocardial Infarction Epidemiology Segmentation
The DelveInsight epidemiological assessment evaluates AMI patient burden across several key categories:
- Total Acute Myocardial Infarction Incident Cases
- Type-specific Incident Cases
- STEMI
- NSTEMI
- Gender-specific Incident Cases
- Male
- Female
According to DelveInsight estimates, approximately 1.5 million AMI incident cases were reported across the 7MM in 2025, with the United States recording the highest number of cases.
Among the 7MM population in 2025, approximately 950,000 cases occurred in males and 550,000 in females. The epidemiological analysis therefore indicates a higher incident burden among males.
The 2025 AMI population was estimated to include approximately 510,000 STEMI cases and 990,000 NSTEMI cases across the 7MM. While STEMI represents a smaller proportion of cases, it is associated with higher immediate mortality and requires urgent reperfusion therapy.
Among the EU4 and the UK, Germany recorded the highest number of AMI incident cases, whereas Spain recorded the lowest number in 2025.
Current Treatment Landscape
AMI treatment focuses on rapid diagnosis, restoration of coronary blood flow, prevention of additional thrombosis, management of ischemia, and long-term reduction of recurrent cardiovascular risk.
Acute Reperfusion
In STEMI, primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy when available within the appropriate timeframe. When PCI cannot be provided promptly, fibrinolytic therapy such as tenecteplase may be used to achieve rapid reperfusion.
Antiplatelet and Anticoagulant Therapy
Immediate antiplatelet therapy, including aspirin with or without a P2Y12 inhibitor, and anticoagulation constitute important components of acute AMI management. These treatments help prevent thrombus propagation and support reperfusion strategies.
Long-term Secondary Prevention
Long-term management generally includes dual antiplatelet therapy, beta-blockers, ACE inhibitors or ARBs, and statins, depending on the patient’s clinical characteristics. Lipid-lowering and anti-inflammatory therapies are increasingly being incorporated to address residual cardiovascular risk.
Approved Therapies
LODOCO (Colchicine) – AGEPHA Pharma
LODOCO (colchicine) is an anti-inflammatory therapy approved to reduce the risk of recurrent cardiovascular events. Within the AMI landscape, it is positioned as an adjunctive treatment in the post-myocardial infarction setting and targets residual inflammation that may contribute to subsequent cardiovascular events.
TNKase (Tenecteplase) – Genentech
TNKase (tenecteplase) is a recombinant fibrinolytic therapy used in AMI to facilitate rapid reperfusion by dissolving coronary thrombi. Its longer half-life and single-bolus administration provide practical advantages over alteplase, particularly when timely primary PCI is unavailable.
REPATHA (Evolocumab) – Amgen
REPATHA (evolocumab) is a monoclonal antibody targeting PCSK9 and is used for intensive LDL-cholesterol lowering in high-risk cardiovascular patients, including individuals with a history of myocardial infarction. The therapy is administered subcutaneously.
Emerging Therapies and Pipeline
Selatogrel (ACT-246475) – Idorsia Pharmaceuticals and Viatris
Selatogrel is a potent, fast-acting, reversible, and selective P2Y12 inhibitor being developed for patients with a history of AMI. The therapy is designed for subcutaneous self-administration through an autoinjector, potentially allowing treatment to begin during the critical period between symptom onset and first medical attention. The asset is listed in Phase III development.
Dutogliptin (REC-01) – Recardio
Dutogliptin is a selective DPP-4 inhibitor being investigated as a subcutaneous treatment following PCI and stent implantation. The development program evaluates dutogliptin in combination with G-CSF, with the approach intended to support myocardial recovery following AMI.
FARXIGA/FORXIGA (Dapagliflozin) – AstraZeneca
Dapagliflozin, marketed as FARXIGA/FORXIGA, is an SGLT2 inhibitor being investigated in patients without diabetes who experience AMI and are at increased risk of subsequently developing heart failure. The asset is listed as a Phase III candidate in the DelveInsight report.
FDY-5301 – Faraday Pharmaceuticals
FDY-5301 is an investigational antioxidant therapy being developed for ischemia-reperfusion injury following myocardial infarction. It is administered through an IV bolus injection and is listed in Phase III development.
Other Emerging Approaches
The broader pipeline also includes zalunfiban (RUC 4), ziltivekimab, milvexian, and olpasiran, which are being investigated across mechanisms addressing thrombosis, inflammation, and lipid-related cardiovascular risk.
Unmet Needs in Acute Myocardial Infarction
Despite substantial improvements in acute cardiovascular care, several unmet needs continue to affect AMI management:
- Limited treatment options for reperfusion injury
- Need for faster diagnosis and emergency treatment
- Need for improved emergency-care and prevention strategies
- Need for therapies that address residual cardiovascular risk
- Limited longitudinal data regarding medication use
- Misdiagnosis and delayed recognition of AMI
- Need for improved long-term prevention of recurrent cardiovascular events
The continued development of therapies addressing thrombosis, inflammation, ischemia-reperfusion injury, and lipid-driven risk represents an important area of innovation in AMI.
Scope of the Acute Myocardial Infarction Market Report
The Acute Myocardial Infarction Market Report – 2036 provides a comprehensive assessment of the AMI therapeutic and epidemiological landscape, including:
- Historical and forecasted market size from 2022–2036
- Epidemiological analysis across the 7MM
- Total AMI incident population
- STEMI and NSTEMI patient burden
- Gender-specific epidemiology
- Current treatment practices and treatment algorithms
- Marketed and emerging therapies
- Clinical development and pipeline analysis
- Competitive landscape
- Market drivers and barriers
- Unmet medical needs
- Drug uptake and peak patient-share analysis
- Pricing and analogue assessment
- Reimbursement and market-access analysis
- KOL and physician insights
- SWOT and conjoint analysis
- Market opportunity assessment
The study covers the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan, with the historical period spanning 2022–2025, the forecast period covering 2026–2036, and 2026 as the base year.
To know more about Acute Myocardial Infarction companies and emerging therapies, request a sample copy of the report: Request Sample Report
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary
- Key Events
- Epidemiology and Market Forecast Methodology of Acute Myocardial Infarction
- Acute Myocardial Infarction Market Overview at a Glance
- Disease Background and Overview of Acute Myocardial Infarction
- Acute Myocardial Infarction Treatment Landscape
- Epidemiology and Patient Burden
- Drug Analysis and Competitive Landscape
- Marketed/Approved Therapies
- Emerging Therapies
- Drug Uptake and Market Forecast
- Market Access and Reimbursement
- Pricing and Analogue Assessment
- Industry Expert and Physician Views
- SWOT and Conjoint Analysis
- Market Drivers and Barriers
- Unmet Needs
- Market Opportunity and Future Outlook
- Report Scope and Methodology
- Appendix
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Contact Person: Kirti Sharma Email: [email protected] Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
